N/A
N=80,452
High-risk Influenza Vaccine Alert
Influenza
Bottom Line
View on ClinicalTrials.gov: NCT05492786 ↗Enrolled (actual)
80,452
Serious AEs
—
Results posted
May 2024
Primary outcome: Primary: Flu Vaccination — 4459; 4456; 4575 Participants — p=0.517
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Alert (Behavioral); Salient alert features (Behavioral); High-risk Text (Behavioral); Risk factors (Behavioral)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Geisinger Clinic
- Primary completion
- Apr 2023
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Flu Vaccination |
4459; 4456; 4575 | 0.517 |
Summary
The purpose of this study is to assess, prospectively, the effect on flu vaccination rates of salient alerts in the electronic health record that indicate a patient's high risk for flu and its complications. The investigators hypothesize that the salient alerts will lead to increased flu vaccination compared with a standard flu alert.
Eligibility Criteria
Patient Inclusion Criteria:
- Age 18+
- Have been determined to be in the top 20% of risk through Medial's ML algorithm
- Attend an appointment where the flu alert fires (Geisinger sets when flu alerts start and end--between ~9/1/2022 and ~4/30/2023, as well as the trigger conditions for the alert, which includes valid departments and visits and excludes contraindications like Guillain-Barre syndrome)
Clinician Inclusion Criteria:
- Any Geisinger clinician who sees patient-participants in our study for an appointment where their flu shot alert fires
Data sourced from ClinicalTrials.gov (NCT05492786). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.